https://www.selleckchem.com/pr....oducts/iwr-1-endo.ht
ve treatment option for advanced EGFR-mutant NSCLC patients. Our results could serve as both a reference for both clinical practice and the formulation of medical insurance reimbursement. No relapse risk prediction tool is currently available to guide treatment selection for multiple sclerosis (MS). Leveraging electronic health record (EHR) data readily available at the point of care, we developed a clinical tool for predicting MS relapse risk. Using data from a clinic-based research registry and linked EHR system between 2006 and 20
Like
Comment
Share
